Timeline® Named Milestone 1 Award Winner in XPRIZE Healthspan Competition
Share this article
Timeline®, a leading longevity biotech company (parent company Amazentis in Canton of Vaud) and maker of Mitopure®, has been named a Milestone 1 Award Winner in the prestigious XPRIZE Healthspan competition. Selected from hundreds of global entrants, Timeline is among the Top 40 international teams recognized for advancing innovative, safe, and science-backed solutions to extend healthy human function by at least a decade.
The XPRIZE Healthspan initiative, launched in 2023, seeks to identify breakthrough interventions capable of restoring muscle, brain, and immune function lost to age-related decline—targeting improvements of 10 to 20 years within a 12-month period for individuals aged 50 to 80. Timeline’s recognition is based on the safety, feasibility, and transformative potential of its interventions.
“XPRIZE is validating what we’ve believed for years—that the science of ageing is ready to deliver real, actionable breakthroughs in human health,” said Dr. Patrick Aebischer, MD, Co-Founder of Timeline and President Emeritus of EPFL. “This recognition highlights the importance of mitochondrial health as a transformative approach to extending healthspan.”
Timeline has led pioneering clinical research in mitochondrial health for over 15 years, discovering and developing Urolithin A, a compound that enhances mitophagy. Its proprietary form, Mitopure®, is clinically proven to boost mitochondrial function, strength, and immune fitness.
“We’re honored to be named among the top 40 global teams advancing clinically backed solutions to extend healthspan,” said Chris Rinsch, PhD, Co-Founder and President of Timeline. “This milestone reflects our commitment to science and innovation in the longevity space.”
Backed by over 50 patents and supported by Nestlé Health Science and L’Oréal, Timeline continues to lead the way in the future of healthy ageing.
➡️ Source: Timeline® | 📸 Timeline